title: Effects of a new Ca2+ antagonist, KB-2796, on the regional cerebral blood flow and somatosensory evoked potentials in the ischemic brain in cats.
abstract: Effects of a new Ca2+ antagonist, 1-[bis(4-fluorophenyl) methyl]-4-(2,3,4-trimethoxybenzyl) piperazine dihydrochloride (KB-2796), on the regional cerebral blood flow (rCBF) and somatosensory evoked potentials (SEPs) were investigated using a model of focal cerebral ischemia in cats. In experiment 1, an occlusion of the middle cerebral artery for 4 hours persistently reduced the ipsilateral rCBF in both the control and the KB-2796-treated groups. However, the flow reduction was much milder in the treatment group than in the control group. Amplitudes of the SEPs diminished in both groups but the rate of deterioration was much slower in the treatment group than in the control group. In experiment 2, an occlusion of the middle cerebral artery for 1 hour was followed by reperfusion for 3 hours. The ipsilateral rCBF decreased during occlusion in both the control and the treatment groups. In the control group, postischemic hyperperfusion was seen in the ectosylvian gyrus after reperfusion, whereas the ipsilateral rCBF recovered rapidly to the control values without showing a phase of hyperperfusion in the treatment group. The rate of recovery of the SEPs was also much more rapid in the treatment group.
authors.affiliation: Department of Neurosurgery, Shiga University of Medical Science, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Harada
authors.forename: Y
authors.initials: Y
authors.lastname: Nakasu
authors.forename: M
authors.initials: M
authors.lastname: Matsuda
authors.forename: J
authors.initials: J
authors.lastname: Handa
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002415:Cats; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical; D005073:Evoked Potentials, Somatosensory / Q000187:drug effects*; D005260:Female; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010879:Piperazines / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D002121:Calcium Channel Blockers; D010879:Piperazines; C052424:lomerizine